SOTIO Presents Data on SOT201 Immunocytokine at SITC Annual Meeting
Mere days after announcing that trials for its lead IL-15 asset have been halted over poor data, Sotio Biotech has unveiled plans to delve deeper into antibody-drug conjugates (ADCs) courtesy of deal worth $740 million in biobucks.
AMSTERDAM, Oct. 16, 2023 /PRNewswire/ -- Synaffix B.V., a Lonza company (SIX:LONN) focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, enters licensing agreement with SOTIO Biotech (SOTIO), a clinical stage immuno-oncology company owned by PPF Group.
SOTIO Further Expands Next-Generation ADC Platform with License to Synaffix’s ADC Technology
SOTIO Provides Update on Interim Data from Clinical Trials of Nanrilkefusp Alfa
Czech biotech Sotio is immediately scrapping three clinical trials of its interleukin-15 superagonist called nanrilkefusp alfa after interim data showed “insufficient efficacy.”
SOTIO Announces First Patients Dosed in Two Combination Arms of CLAUDIO-01 Study Evaluating SOT102 in First-Line Gastric and Pancreatic Cancer
SOTIO Doses First Patient in AURELIO-05 Phase 2 Trial of Nanrilkefusp Alfa in Combination with Cetuximab
BASEL and CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, presented preclinical data evaluating the mechanism of action and metabolic function of its BOXR T cell platform in a poster presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, taking place in Boston, Massachusetts from November 8-12, 2022. An additional poster was presented on the trial design of AURELIO-04, an ongoing Phase 2 study evaluating the efficacy and safety of SOT101 in combination with pembrolizumab in patients with advanced solid tumors.
BASEL, Switzerland and CAMBRIDGE, Mass., Oct. 18, 2022 (GLOBE NEWSWIRE) -- SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announced today that it will share two poster presentations, namely the Phase 2 AURELIO-04 study design of the IL-15 superagonist, SOT101 as a Trial in Progress and nonclinical data on mechanism of action of its BOXR T cell platform, at the upcoming Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, taking place in Boston, Massachusetts from November 8-12, 2022.